<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>kırıkkale uni med j</journal-id>
            <journal-title-group>
                                                                                    <journal-title>The Journal of Kırıkkale University Faculty of Medicine</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2148-9645</issn>
                                                                                            <publisher>
                    <publisher-name>Kirikkale University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.24938/kutfd.1025242</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Health Care Administration</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Sağlık Kurumları Yönetimi</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="en">
                                    <trans-title>Kinesiophobia in Fibromyalgia Syndrome: Relationship with Obesity, Pain Intensity,  High Disease Activity</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>FİBROMYALJİ SENDROMUNDA KİNEZYOFOBİ: OBEZİTE, AĞRI ŞİDDETİ, YÜKSEK HASTALIK AKTİVİTESİ İLİŞKİSİ</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0003-0542-266X</contrib-id>
                                                                <name>
                                    <surname>Aydogan Baykara</surname>
                                    <given-names>Rabia</given-names>
                                </name>
                                                                    <aff>MALATYA TURGUT OZAL UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, DEPARTMENT OF PHYSICAL MEDICAL TREATMENT AND REHABILITATION</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20220430">
                    <day>04</day>
                    <month>30</month>
                    <year>2022</year>
                </pub-date>
                                        <volume>24</volume>
                                        <issue>1</issue>
                                        <fpage>128</fpage>
                                        <lpage>135</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20211118">
                        <day>11</day>
                        <month>18</month>
                        <year>2021</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20220307">
                        <day>03</day>
                        <month>07</month>
                        <year>2022</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1999, The Journal of Kırıkkale University Faculty of Medicine</copyright-statement>
                    <copyright-year>1999</copyright-year>
                    <copyright-holder>The Journal of Kırıkkale University Faculty of Medicine</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="en">
                            <p>Objective: It was aimed to investigate the relationship between disease severity and kinesiophobia in Fibromyalgia Syndrome.Material and Methods: This study, which was planned as a prospective, cross-sectional, case-control study, included 149 patients between the ages of 21-67 who were diagnosed with FMS according to American College of Rheumatology 2010 criteria and 92 healthy controls with similar characteristics. Fibromyalgia Impact Questionnaire was used for disease severity, visual analog scale was used for pain severity, and Tampa Kinesiophobia Scale was used for kinesiophobia. Demographic data such as age, gender, body mass index of the patients were recorded.Results: Demographic data were similar between the patient group (n=149) and the healthy control group (n=92). When Tampa Kinesiophobia Scale was compared with 41.51 (SD: 7.31) in the patient group and 35.71 (SD: 8.98) in the control group, there was a significant difference (p&amp;lt;0.01). There was a significant correlation between disease severity and kinesiophobia (p&amp;lt;0.01). Visual analog scale and Fibromyalgia Impact Questionnaire values were also significantly different in the patient group compared to the control group (p&amp;lt;0.01). There was no significant relationship between body mass index low group (25 kg/m2 and below) and body mass index high group (25 kg/m2 above) and kinesiophobia.Conclusion: As the severity of the disease increases in fibromyalgia syndrome, kinesiophobia also increases. Therefore, kinesiophobia should be kept in mind when planning treatment in patients with Fibromyalgia Syndrome.</p></trans-abstract>
                                                                                                                                    <abstract><p>Amaç: Fibromiyalji sendromunda hastalık şiddeti ile kinezyofobi arasındaki ilişkinin araştırılması amaçlandı.Gereç ve Yöntemler: Prospektif, kesitsel, vaka kontrol araştırması olarak planlanan bu çalışmaya Amerikan Romatoloji Koleji 2010 kriterlerine göre Fibromiyalji sendromu tanısı almış 21-67 yaş arası 149 hasta ile benzer özellikte 92 sağlıklı kontrol dâhil edildi. Hastalık şiddeti için Fibromiyalji Etki Anketi, ağrı şiddeti için vizüel analog skala, kinezyofobi için Tampa Kinezyofobi Ölçeği kullanıldı. Hastaların yaş, cinsiyet, vücut kitle indeksi gibi demografik verileri kaydedildi.Bulgular: Hasta grubu ve sağlıklı kontrol grubu arasında demografik veriler benzerdi. Tampa Kinezyofobi Ölçeği, hasta grubunda ortalama 41.51 (SS:7.31), kontrol grubunda ortalama 35.71 (SS:8.98) olarak bulunmuş olup anlamlı fark vardı (p&amp;lt;0.01. Hastalık şiddeti ile kinezyofobi arasında anlamlı korelasyon mevcuttu (p&amp;lt;0.01). Vizüel analog skala, Fibromiyalji Etki Anketi değerleri ise hasta grubunda kontrol grubuna göre anlamlı farklıydı (p&amp;lt;0.01). Vücut kitle indeksinin düşük (25 kg/m2 ve altı) ve yüksek grupları (25 kg/m2 üstü) ile kinezyofobi arasında anlamlı ilişki yoktu.Sonuç: Fibromiyalji sendromunda hastalık şiddeti arttıkça kinezyofobi de artmaktadır. Bu nedenle fibromiyalji sendromlu hastalarda tedavi planlarken kinezyofobi akılda tutulmalıdır.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Fibromiyalji Sendromu</kwd>
                                                    <kwd>  Kinezyofobi</kwd>
                                                    <kwd>  Tampa Kinezyofobi Ölçeği</kwd>
                                                    <kwd>  Fibromiyalji Etki Anketi</kwd>
                                                    <kwd>  Hareket Korkusu</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="en">
                                                    <kwd>Fiibromialgia Syndrome</kwd>
                                                    <kwd>  Kinesiophobia</kwd>
                                                    <kwd>  Tampa Scale of Kinesiophobia</kwd>
                                                    <kwd>  Fibromialgia Impact Questionnaire</kwd>
                                                    <kwd>  Fear of  Movement</kwd>
                                            </kwd-group>
                                                                                                                                    <funding-group specific-use="FundRef">
                    <award-group>
                                                    <funding-source>
                                <named-content content-type="funder_name">Destekleyen kurum bulunmamaktadır</named-content>
                            </funding-source>
                                                                            <award-id>(No:2021/5), Turgut Özal Girişimsel olmayan etik kurulundan onay alınmıştır</award-id>
                                            </award-group>
                </funding-group>
                                </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1.	Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020;172(5):33-48.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2.	Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645-60.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3.	Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017:76(2);318-28.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4.	Langhorst J, Heldmann P, Henningsen P, Kopke K, Krumbein L, Lucius H et al. Complementary and alternative procedures for fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):289-95.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5.	Schiltenwolf M, Eidmann U, Köllner V, Kühn T, Offenbächer M, Petzke F et al. Multimodal therapy of fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles. Schmerz. 2017;31(3):285-8.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6.	Damas PR, Marín BF, Sánchez MF, Larrea VP. Fibromyalgia syndrome and fear. Aten Primaria. 2021;53(9):102137.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7.	Andrade A, Torres Vilarino G, Mendes Sieczkowska S, Reis Coimbra D, Klumb Steffens RA, Grunewald Vietta G. Acute effects of physical exercises on the inflammatory markers of patients with fibromyalgia syndrome: A systematic review. J Neuroimmunol. 2018;316:40-9.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8.	Kori SH, Miller RP, Todd DD. Kinesiophobia: A new view of chronic pain behavior. Pain Manage 1990;3:35-43.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9.	Russek L, Gardner S, Maguire K, Stevens C, Brown EZ, Jayawardana V et al. A cross-sectional survey assessing sources of movement-related fear among people with fibromyalgia syndrome. Clin Rheumatol. 2015;34(6):1109-19.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10.	Varallo G, Scarpina F, Giusti EM, Cattivelli R, Usubini AG, Capodaglio P et al. Does kinesiophobia mediate the relationship between pain intensity and disability in individuals with chronic low-back pain and obesity? Brain Sci. 2021;11(6):684.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11.	Wolfe F, Walitt BT, Katz RS, Häuser W. Social security work disability and its predictors in patients with fibromyalgia. Arthritis Care Res. 2014;66(9):1354-63.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12.	Turk DC, Robinson JP, Burwinkle T. Prevalence of fear of pain and activity in patients with fibromyalgia syndrome. J Pain. 2004;5(9):483-90.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13.	Leeuw M, Goossens ME, Linton SJ, Crombez G, Boersma K, Vlaeyen JW. The fear-avoidance model of musculoskeletal pain: current state of scientific evidence. J Behav Med. 2007;30(1):77-94.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14.	Koçyiğit BF, Akaltun MS. kinesiophobia levels in fibromyalgia syndrome and the relationship between pain, disease activity, depression. Arch Rheumatol. 2020;35(2):214-9.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15.	Jiménez-Cebrián AM, Becerro-de-Bengoa-Vallejo R, Losa-Iglesias ME, de Labra C, Calvo-Lobo C, Palomo-López P et al. Kinesiophobia levels in patients with parkinson&#039;s disease: a case-control investigation. Int J Environ Res Public Health. 2021;18(9):4791.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16.	Wasiuk-Zowada D, Knapik A, Szefler-Derela J, Brzęk A, Krzystanek E. kinesiophobia in stroke patients, multiple sclerosis and parkinson&#039;s disesase. Diagnostics (Basel). 2021;11(5):796.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17.	Lundberg M, Styf J, Jansson B. On what patients does the Tampa Scale for Kinesiophobia fit? Physiother Theory Pract. 2009;25(7):495-506.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18.	Yilmaz ÖT, Yakut Y, Uygur F, Uluğ N. Tampa Kinezyofobi Ölçeği’nin Türkçe versiyonu ve test-tekrar test güvenirliği. Fizyoterapi Rehabilitasyon. 2011;22(1),44-9.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19.	Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23(5):154-62.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20.	Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int. 2000;20(1):9-12.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21.	Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63 (11):240-52.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22.	Velasco L, López-Gómez I, Gutiérrez L, Écija C, Catalá P, Peñacoba C. Exploring the preference for fatigue-avoidance goals as a mediator between pain catastrophizing, functional impairment, and walking behavior in women with fibromyalgia. Clin J Pain. 2021;38(3):182-8.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23.	Vincent HK, Omli, MR, Day T, Hodges M, Vincent KR, George SZ. Fear of movement, quality of life, and self-reported disability in obese patients with chronic lumbar pain. Pain Med. 2011;12(1):154-64.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24.	Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain. 2000;85(3):317-32.</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25.	Varallo G, Scarpina F, Giusti EM, Suso-Ribera C, Cattivelli R, Guerrini Usubini A et al. The role of pain catastrophizing and pain acceptance in performance-based and self-reported physical functioning in individuals with fibromyalgia and obesity. J Pers Med. 2021;11(8):810.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26.	Okifuji A, Donaldson GW, Barck L, Fin, PG. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. J Pain. 2010;11(12):1329-37.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27.	Burwinkle T, Robinson JP, Turk DC. Fear of movement: factor structure of the tampa scale of kinesiophobia in patients with fibromyalgia syndrome. J Pain. 2005;6(6):384-91.</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28.	Turk DC, Okifuji A, Starz TW, Sinclair JD. Effects of type of symptom onset on psychological distress and disability in fibromyalgia syndrome patients. Pain. 1996;68(2-3):423-30.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
